Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carmegliptin dose-ranging study in type 2 diabetes
NCT00502710Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of carmegliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Roche. Primary endpoint: Absolute change in hemoglobin A1c at 12 weeks. Started Jul 2007; status: completed.
02
Drugs
carmegliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00502710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502710.